OBJECTIVES
To compare a commercially available artificial intelligence (AI) risk-classification system with PI-RADS for detecting clinically significant prostate cancer (csPCa) on prostate MRI.
MATERIALS AND METHODS
This retrospective multicentre, multivendor diagnostic accuracy study included men who underwent prost...
Karsten Guenzel, Maarten G. Poirot, Almar van Loon et al.· European Radiology· 0 citations
Abstract Prostate imaging, and especially multiparametric magnetic resonance imaging (mpMRI), has become central to the diagnosis, risk stratification, treatment planning, and follow-up of prostate cancer. Its widespread adoption has driven the development of structured imaging scoring systems designed to standardize a...
E. Messina, Antonella Borrelli, Georgios Agrotis et al.· BJR|Open· 0 citations
Prostate-specific antigen (PSA)-based screening for prostate cancer (PCa) remains controversial due to uncertain long-term benefits, overdiagnosis, and overtreatment of indolent disease. Magnetic resonance imaging (MRI) has transformed the diagnostic pathway of PCa and is increasingly explored as a screening tool. This...
Giorgio Brembilla, E. Messina, Tristan Barret et al.· European Radiology· 0 citations
To compare the diagnostic performance of MRI using the PI-RR scoring system and PSMA-PET/CT in detecting prostate cancer (PCa) local recurrence after radical prostatectomy (RP), and to identify clinical and imaging variables independently associated with recurrence. This retrospective, multicenter study evaluated 119 p...
L. Laschena, Martina Pecoraro, E. Messina et al.· La radiologia medica· 0 citations
The gap between AI's research promise and clinical readiness is highlighted, which underscores the need for localvalidation, post-market surveillance, and adequate user training as AI tools become incorporated into diagnostic prostate MRI workflows.
Renato Cuocolo, A. Ponsiglione, G. Agrotis et al.· European Radiology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.